SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs Phase 3 REGAL trial is the dominant focus, with traders awaiting confirmation of the 80th death that triggers final analysis; the last disclosed count was 78, and speculation links the prolonged wait and company silence to possible ASH disclosures. Bulls interpret the delay as a potential sign of longer survival, while bears question the trial timeline and warn that the outcome remains uncertain; the debate accompanies a sharp share-price decline.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

ESMO data on Iovances lifileucel program is the main focus, especially mature frontline melanoma results for lifileucel plus pembrolizumab and early sarcoma findings. Traders highlight durable melanoma responses as supportive of expansion into earlier treatment, while others caution that the cohorts are small and the sarcoma response rate eased as the sample grew.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

A broad selloff in AI neocloud stocks, driven by worries about debt, financing costs, and whether rapid data-center spending can earn adequate returns, has weighed on Nebius alongside peers. Traders are divided: bears see further valuation pressure, while bulls argue Nebius is better positioned than more leveraged rivals and view the drop as an overdone sector-wide move.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A Nasdaq-futures rebound around the 1987 Black Monday anniversary is dominating discussion after a steep tech-led selloff, with big-tech earnings ahead. Traders are split on whether the bounce is a durable recovery or a short-covering rally that could fade, while AI-stock weakness and broader market risks remain concerns.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

A sharp futures rebound after last weeks tech-led selloff has shifted the conversation to whether the bounce will hold, amid fears tied to the Black Monday anniversary. Bulls call it a relief rally or short squeeze and dismiss crash worries, while skeptics warn the move may fade; upcoming megacap earnings add to market focus.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Concern over IPO lockup expirations and the potential for insider-share selling is a recurring focus as CBRS faces a steep decline. Traders also point to weakness across AI and semiconductor stocks and question the companys high valuation, growth prospects, and reliance on OpenAI; others argue the selloff is overdone and are buying the dip.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

XBI is drawing attention amid a broad biotech selloff, which traders attribute to rising-rate concerns, risk-off positioning and rotation between biotech and AI/technology stocks. The community is split between calling the decline capitulation and buying the dip, and warning that sector weakness could continue; no company-specific catalyst dominates.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerrys QNX growth storyparticularly a major Alloy Kore vehicle-platform design win and an Uber design win, alongside stronger results and a raised outlookis driving discussion. Bullish traders see potential in software-defined vehicles and physical AI, while skeptics question how quickly design wins will translate into revenue and note the share-price weakness.

GEOM maps the world's oil fields, mines, rare earths, and power plants, tracks what is and isn't tokenized, and cryptographically signs every dataset it publishes. Anyone can verify what we said and when. No account, no key, no permission. Sources include the WRI Global Power Plant Database and Global Energy Monitor (CC BY 4.0), attributed in full inside the app. Most of it already exists, spread across filings and terminals no one reads. GEOM gathers it and records where each figure came from.

GEOM

Attention centers on the proposed GEOM platform for tokenizing energy and mineral assets and royalties, which traders link to Greenland Energy and USFM; bullish holders are anticipating a platform demo, launch, or partner announcement. Others question the tokens verified utility and connections, citing thin liquidity, sharp swings, and rug-pull risk.

United Airlines Holdings, Inc. is a holding company, which engages in the provision of transportation services. It operates through the following geographical segments: Domestic, Atlantic, Pacific, and Latin America. The company was founded on December 30, 1968 and is headquartered in Chicago, IL.

United Airlines Holdings Inc

UAL is drawing attention ahead of its Q3 earnings report, with traders focused on whether strong travel demand and fare increases can offset elevated jet-fuel costs and recently lowered earnings expectations. Bulls point to Uniteds prior earnings beats and pricing power, while bears worry about margin pressure, analyst downgrades, and another selloff even if results top estimates.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Niagen Bioscience to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that it will hold a conference call on Wednesday, November 4, 2026, at 4:30 p.m. ET to discuss its financial results for the third...

Andrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, Honored with the 2026 Annette Dickinson Trailblazer Award by Radicle Science and Council for Responsible Nutrition (CRN)

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that Radicle Science and Council for Responsible Nutrition (CRN) honored Andrew Shao, Ph.D., Senior Vice President of Global...

Niagen Bioscience to Present at LD Micro 20th Annual Main Event

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will participate in the 20th Annual LD Micro Main Event from Monday, October 19 to 21, 2026, in Los Angeles...

Niagen Bioscience Puts 25 Years of NAD+ Science Behind "Don't Get Old. Age Better. a New Campaign for its Niagen Brand Featuring Legendary Surfer Kelly Slater

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the launch of Don't Get Old. Age Better., a new brand campaign for its Niagen (patented nicotinamide riboside, or NR) brand and...

Niagen Bioscience Announces Start-Up Agreement With Mass General Brigham (MGB) Investigators For First-Of-Its-Kind Healthy Aging Clinical Trial

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced a Start-Up Agreement with Mass General Brigham (MGB) to begin detailed planning for what is envisioned to be the largest and most...

Newly Published Preclinical Study Demonstrates CD38 as a Driver of Age-Related NAD+ Decline, Older Mothers Have Lower NAD+ Levels in Placental Tissue, and NAD+ Restoration with Nicotinamide Riboside (NR) Improves Pregnancy Outcomes

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces the publication of independent preclinical research in Nature Communications led by a team at Sichuan Agricultural University...

Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces today that its wholly owned subsidiary, NAD Pharmaceuticals Corp., has engaged Red Sky Partners, a life sciences strategic advisory firm...

Niagen Bioscience to Present at Canaccord Genuitys Well Summit

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Ozan Pamir, will participate in Canaccord Genuitys Well...

Niagen Bioscience to Present at Longevity Investors Conference

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will participate at the Longevity Investors Conference, taking place from September 14 to 17, 2026, in...

Niagen Bioscience to Present at Nasdaq X LD Micro Inaugural SF Summit

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will participate in the Nasdaq X LD Micro Inaugural SF Summit on Wednesday, September 9, 2026, in San...

Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, Analytical Reference Standards and Services, and Pharmaceuticals. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The Pharmaceuticals segment focuses on the pharmaceutical development of NAD precursor portfolio for potential therapeutic applications in rare diseases. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

Niagen Bioscience Inc.

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$2.49
Prev Close	$2.58
Open	$2.58
Dividend Yield	0.00%
50-Day Moving Average	$2.98
Beta	1.38
Avg. Volume	379,003.42
PE Ratio	13.23

52-Week High	$7.95
52-Week Low	$2.46
Market Capitalization	$197.02M
EPS (Annual)	$0.2034
Price to Book	2.38
Revenue Per Employee	$1.11M

Feed

News

Sentiment

Earnings

Fundamentals

Info

NAGE Fundamentals